Business Of Biotech Biotech Angel Investing With Yaniv Sneor
16 snips
May 26, 2025 Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, dives into the world of life science angel investing. He shares how investors evaluate biotech startups and the importance of crafting a compelling pitch. Yaniv discusses red flags for investors, the role of syndicates, and why biotech remains a strong investment sector. He highlights the intricacies of funding timelines and offers valuable insights for emerging drug developers seeking capital in a competitive landscape.
AI Snips
Chapters
Transcript
Episode notes
Focus On Manageable Time And Funds
- Target biotech investments with exit timelines of 5-7 years to limit risk.
- Invest in companies needing smaller rounds to avoid dilution and maintain control.
Biotech's Unique Investment Appeal
- Biotech offers a unique combination of high risk and high reward.
- It demands maturity due to required data and regulatory rigor.
Tailor Pitches To Investors
- Avoid generic, untargeted pitches that ignore specific investment criteria.
- Present financial opportunity clearly, not just scientific data.